Genfit’s (GNFT) Buy Rating Reaffirmed at HC Wainwright

Genfit (NASDAQ:GNFT)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $13.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 134.61% from the company’s current price.

Genfit Price Performance

NASDAQ:GNFT opened at $5.54 on Friday. The business’s 50-day moving average is $4.54 and its 200 day moving average is $4.23. Genfit has a 12 month low of $2.97 and a 12 month high of $6.05. The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.